A phase II trial of ZD1839 (Iressa?) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor—Based Chemotherapy in Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.3816/ccc.2006.n.022 ◽

2006 ◽

Vol 6 (1) ◽

pp. 59-65 ◽

Cited By ~ 8

Author(s):

Jeffrey A. Meyerhardt ◽

Denise Heseltine ◽

Shuji Ogino ◽

Jeffrey W. Clark ◽

Peter C. Enzinger ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

KRASstatus and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis

Colorectal Disease ◽

10.1111/codi.12749 ◽

2014 ◽

Vol 16 (11) ◽

pp. O370-O378 ◽

Cited By ~ 8

Author(s):

W. Li ◽

Q. Shi ◽

W. Wang ◽

J. Liu ◽

J. Ren ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Inhibitor Treatment

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

European Journal of Cancer ◽

10.1016/s0959-8049(01)80551-7 ◽

2001 ◽

Vol 37 ◽

pp. S18-S19 ◽

Cited By ~ 6

Author(s):

L. Hammond ◽

J. Figueroa ◽

L. Schwartzberg ◽

L. Ochoa ◽

M. Hidalgo ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Colorectal Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Egfr Tki

ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

British Journal of Cancer ◽

10.1038/sj.bjc.6600182 ◽

2002 ◽

Vol 86 (7) ◽

pp. 1157-1161 ◽

Cited By ~ 133

Author(s):

K J Williams ◽

B A Telfer ◽

I J Stratford ◽

S R Wedge

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Xenograft Model ◽

Growth Factor Receptor ◽

Human Colorectal Cancer ◽

1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)91112-8 ◽

2003 ◽

Vol 1 (5) ◽

pp. S325 ◽

Cited By ~ 3

Author(s):

E. Van Cutsem ◽

P. Gascón Vilaplana ◽

J.F. Seitz ◽

J.L. Van Laethem ◽

F. Grossi ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Trial ◽

Single Agent ◽

Growth Factor Receptor ◽

Randomized Phase Ii ◽

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer

PLoS ONE ◽

10.1371/journal.pone.0101019 ◽

2015 ◽

Vol 10 (5) ◽

pp. e0101019 ◽

Cited By ~ 1

Author(s):

Ze Li ◽

Xue-Wei Liu ◽

Zhao-Cheng Chi ◽

Bao-Sheng Sun ◽

Ying Cheng ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Growth Factor Receptor ◽

Ras Mutations ◽

54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90089-9 ◽

2003 ◽

Vol 1 (5) ◽

pp. S21 ◽

Cited By ~ 3

Author(s):

J. Patel ◽

V. Miller ◽

M. Kris ◽

N. Shah ◽

L. Tyson ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Active Agent ◽

Growth Factor Receptor ◽

Bronchioloalveolar Carcinoma ◽

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

10.32388/jfobd7 ◽

2020 ◽

Author(s):

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Association between E-cadherin and sensitivity of hepatocellular carcinoma to treatment with epidermal growth factor receptor tyrosine kinase inhibitor

Academic Journal of Second Military Medical University ◽

10.3724/sp.j.1008.2014.00915 ◽

2014 ◽

Vol 35 (8) ◽

pp. 915

Author(s):

Rong-chun XING ◽

Jun ZHENG ◽

Ping CHEN ◽

Wei-hong ZHENG ◽

Wei LIU ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer

Recent Patents on Anti-Cancer Drug Discovery ◽

10.2174/1574209199544168928 ◽

2009 ◽

Vol 999 (999) ◽

pp. 1-8

Author(s):

Anne Kendall ◽

Rosemary Lord ◽

Nick Maisey

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Receptor Antibodies